Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wayne E. Richenbacher is active.

Publication


Featured researches published by Wayne E. Richenbacher.


Circulation | 1998

Evidence for a Central Origin of the Low-Frequency Oscillation in RR-Interval Variability

Ryan L. Cooley; Nicola Montano; Chiara Cogliati; Philippe van de Borne; Wayne E. Richenbacher; Ron M. Oren; Virend K. Somers

BACKGROUND Short-term variability of RR interval and blood pressure occurs predominantly at low frequency (LF; approximately 0.1 Hz) and high frequency (approximately 0.25 Hz). The arterial baroreflex is thought to be the predominant determinant of the LF component of RR variability. Patients with severe congestive heart failure (CHF) have an attenuated or absent LF oscillation in RR variability. The left ventricular assist device (LVAD) offers a unique possibility for analysis of spectral oscillations in RR interval independent of any effects of blood pressure that influence these oscillations via the baroreflex. METHODS AND RESULTS We performed spectral analysis of RR, blood pressure, and respiration in 2 patients with CHF before and after LVAD implantation. LF components of the RR-interval and blood pressure variability were absent in both CHF patients before LVAD implantation. After LVAD implantation, spectral analysis of the RR interval showed restoration of a clear and predominant LF oscillation in the native hearts of both patients, with no such oscillation evident in the blood pressure profile. CONCLUSIONS During total circulatory support with the LVAD, the LF oscillation in RR interval of the native heart, absent in CHF, is restored. This LF oscillation in RR interval occurs in the absence of LF oscillations in blood pressure and thus is unlikely to be explained by baroreflex mechanisms. Hence, the absence of LF oscillation in the RR interval in CHF is functional and is reversible by LVAD circulation. The presence of a predominant LF oscillation in RR interval independent of any oscillation in blood pressure suggests that the LF oscillation is a fundamental property of central autonomic outflow.


Annals of Surgery | 2003

Left Ventricular Assist Devices as Permanent Heart Failure Therapy The Price of Progress

Mehmet C. Oz; Annetine C. Gelijns; Leslie W. Miller; Cuiling Wang; Patrice Nickens; Raymond R. Arons; Keith D. Aaronson; Wayne E. Richenbacher; Clifford H. Van Meter; Karl E. Nelson; Alan D. Weinberg; John T. Watson; Eric A. Rose; Alan J. Moskowitz

Summary Background Data: The REMATCH trial evaluated the efficacy and safety of long-term left ventricular assist device (LVAD) support in stage D chronic end-stage heart failure patients. Compared with optimal medical management, LVAD implantation significantly improved the survival and quality of life of these terminally ill patients. To date, however, there have been no analyses of the cost related to the LVAD survival benefit. This paper addresses the cost of hospital resource use, and its predictors, for long-term LVAD patients. Methods: Detailed cost data were available for 52 of 68 REMATCH patients randomized to LVAD therapy. We combined the clinical dataset with Medicare data, standard billing forms (UB-92), and line item bills provided directly by clinical centers. Charges were converted to costs by using the Ratio-of-Cost-to-Charges for each major resource category. Results: The mean cost for the initial implant-related hospitalization was


Arteriosclerosis, Thrombosis, and Vascular Biology | 2003

Low-Level Endotoxin Induces Potent Inflammatory Activation of Human Blood Vessels: Inhibition by Statins

James Rice; Lynn L. Stoll; Wei Gen Li; Gerene M. Denning; Jamie Weydert; Elizabeth Charipar; Wayne E. Richenbacher; Francis J. Miller; Neal L. Weintraub

210,187 ± 193,295. When implantation hospitalization costs are compared between hospital survivors and nonsurvivors, the mean costs increase from


Transplantation | 1992

OUTCOME OF CARDIAC TRANSPLANT RECIPIENTS WITH A POSITIVE DONOR-SPECIFIC CROSSMATCH—PRELIMINARY RESULTS WITH PLASMAPHERESIS

Ranae M. Ratkovec; Elizabeth H. Hammond; John B. O'Connell; Michael R. Bristow; Charles W. DeWitt; Wayne E. Richenbacher; Roger C. Millar; Dale G. Renlund

159,271 ± 106,423 to


American Journal of Pathology | 2004

Enhanced cytomegalovirus infection in atherosclerotic human blood vessels.

Pamela Nerheim; Jeffery L. Meier; Mohammad A. Vasef; Wei Gen Li; Ling Hu; James Rice; Daniel Gavrila; Wayne E. Richenbacher; Neal L. Weintraub

315,015 ± 278,713. Sepsis, pump housing infection, and perioperative bleeding are the major drivers of implantation cost, established by regression modeling. In the patients who survived the procedure (n = 35), bypass time, perioperative bleeding, and late bleeding were the drivers of cost. The average annual readmission cost per patient for the overall cohort was


Journal of the American College of Cardiology | 1989

Current status of cardiac surgery: A 40 year review

Wayne E. Richenbacher; John L. Myers; John A. Waldhausen

105,326. Conclusions: The cost of long-term LVAD implantation is commensurate with other life-saving organ transplantation procedures like liver transplantation. As an evolving technology, there are a number of opportunities for improvement that will likely reduce costs in the future.


Annals of Biomedical Engineering | 1998

Negative Pressure Transients with Mechanical Heart-Valve Closure: Correlation between In Vitro and In Vivo Results

K. B. Chandran; Elisabeth U. Dexter; Srinivas Aluri; Wayne E. Richenbacher

Background—Low-level endotoxemia (ie, ≥50 pg/mL) in apparently healthy subjects was recently identified as a powerful, independent risk factor for atherosclerosis. Methods and Results—We treated human saphenous veins (HSVs) with low levels of endotoxin. Release of the proinflammatory chemokines interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) was measured by ELISA. Superoxide was determined by using the fluorescent probe dihydroethidium (HE), and monocyte binding was assessed with calcein-labeled U-937 cells. Three- to 4-fold increases in MCP-1 and IL-8 release were observed at endotoxin concentrations of 100 pg/mL; these increases were inhibited by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Studies in cultured endothelial cells suggest that the mechanism is related to inhibition of isoprenylation (ie, geranylgeranylation) rather than cholesterol formation. Endotoxin produced dose-dependent increases in HE fluorescence that were inhibited by the superoxide dismutase mimics Tiron and MnTBAP. Endotoxin potently induced U-937 cell binding to HSV; binding was inhibited by both Tiron and atorvastatin. Toll-like receptor-4 expression was detected in cultured HSV endothelial and smooth muscle cells and in intact HSV. Conclusions—Clinically relevant levels of endotoxin, as reported in ambulatory populations, have profound inflammatory effects on intact HSV. Inhibition of endotoxin-induced vascular inflammation might contribute to the beneficial effects of statins in treating atherosclerosis.


Asaio Journal | 1989

In vivo performance of a transcutaneous energy transmission system with the Penn State motor driven ventricular assist device.

William J. Weiss; Gerson Rosenberg; Alan J. Snyder; Walter E. Pae; Wayne E. Richenbacher; William S. Pierce

To assess the influence of a positive T or B cell IgG crossmatch on the development of rejection and mortality following cardiac transplantation, we reviewed all cardiac transplants performed in Utah between March 1985 and October 1990. Of the 328 cardiac allograft recipients, 11 (3.4%) had an IgG positive crossmatch. Actuarial survival at 24 months in the positive crossmatch group was 57.3% +/- 0.02 while that of the controls was 86.1% +/- 2.1 (P < 0.05). Allograft rejection occurred earlier in recipients with a positive crossmatch (10.0 +/- 5.8 days versus 34.0 +/- 2.3 days, P < 0.001). The first allograft rejection episode in patients with a positive crossmatch was characterized by immunoglobulin and complement deposition in small blood vessels and interstitial edema and endothelial cell activation in the absence of a lymphocytic infiltrate. Furthermore, the allograft rejection in the positive crossmatch group was accompanied by hemodynamic compromise in a large proportion of the patients (73%). In addition to augmentation of immunosuppression, plasma exchange therapy was performed within the first week following transplantation in 8 of the 11 positive crossmatch patients. Survival in the patients treated with plasma exchange (75%) appears to be better than in those not receiving plasma exchange (33%) within one week of transplantation. While immunosuppressive therapy aimed at the humoral arm of the immune system and plasma exchange therapy may improve survival in recipients with a positive donor-specific crossmatch, survival is worse in patients with a positive crossmatch than in patients with a negative crossmatch. Thus, it would appear prudent to prospectively crossmatch cardiac transplant candidates with a greater risk of developing a positive crossmatch, such as those potential recipients with an elevated level of panel-reactive antibodies.


Asaio Journal | 1998

Time Course of Cytokine Release and Complement Activation After Implantation of the Heartmate Left Ventricular Assist Device

David C. Corry; Alphonse DeLucia; Hong Zhu; Robert R. Radcliffe; Gregory R. Brevetti; Hazem El-khatib; Sara J. Vance; Bruce R. Moyer; William G. Cotts; Wayne E. Richenbacher

Human cytomegalovirus (CMV) is a possible co-factor in atherogenesis and vascular occlusion, but its ability to actively infect medium and large blood vessels is unclear. A vascular explant model was adapted to investigate CMV infection in human coronary artery, internal mammary artery (IMA), and saphenous vein (SV). Vascular explants were inoculated with CMV Towne or low-passage clinical isolate and examined in situ for CMV cytopathic effect and immediate-early and early antigens, as indicators of active infection. At 5 to 7 days after inoculation, we found that CMV Towne actively infected eight of eight different atherosclerotic blood vessel explants (coronary artery, n = 4; SV and IMA grafts, n = 4), whereas it only infected 2 of 14 nonatherosclerotic blood vessel explants (SV, n = 10; IMA, n = 4) (P = 0.001). The CMV clinical isolate actively infected none of six sets of nonatherosclerotic SV explants at 5 to 7 days after inoculation. The active CMV infections involved adventitial and, less frequently, intimal cells. A small subset of infected cells in atherosclerotic tissue expresses the endothelial cell marker CD31. Smooth muscle cells residing in both atherosclerotic and nonatherosclerotic blood vessels were free of active CMV infections even after all vascular tissue layers were exposed to the virus. In contrast, active CMV Towne infection was evident at 2 days after inoculation in smooth muscle cells and endothelial cells previously isolated from the SV tissues. We conclude that active CMV infection is enhanced in atherosclerotic blood vessels compared to atherosclerosis-free vascular equivalents, and this viral activity is restricted to subpopulations of intimal and adventitial cells.


Asaio Journal | 2001

Hospital discharge for the ventricular assist device patient: historical perspective and description of a successful program.

Wayne E. Richenbacher; Sarah C. Seemuth

Cardiac surgery has undergone dramatic advancements during the past 3 decades. The introduction of cardiopulmonary bypass and cardioplegic arrest ushered in the true era of open heart surgery. Bioprostheses and mechanical valves as well as techniques for valve reconstruction permit routine repair or replacement of stenotic and regurgitant native valves. Progress in the disciplines of mechanical and electrical engineering has led to the development of pocket watch-sized, physiologically responsive pacemakers as well as a variety of circulatory assist devices that include the intraaortic balloon pump, ventricular assist device and total artificial heart. The synthesis of cardiotonic and vasoactive drugs and advancements in anesthetic management, postoperative monitoring and nursing care greatly facilitate perioperative patient management. This summary of state of the art cardiac surgery begins with a brief historical background followed by a review of recent advances in six main categories: coronary artery disease, acquired valvular heart disease, congenital cardiac disease, cardiac transplantation, myocardial preservation and mechanical circulatory assistance. In conducting the review of recent literature, particular attention was directed to large clinical series that document the results of contemporary surgical procedures, novel therapeutic approaches to current clinical problems and unresolved controversies in the field of cardiac surgery. The abundance of surgical literature and constraints on the length of this article do not permit an exhaustive review. Apologies are extended to clinicians and laboratory investigators whose important contributions to the understanding and treatment of cardiac disease are not included herein.

Collaboration


Dive into the Wayne E. Richenbacher's collaboration.

Top Co-Authors

Avatar

William S. Pierce

Pennsylvania State University

View shared research outputs
Top Co-Authors

Avatar

John A. Waldhausen

Penn State Milton S. Hershey Medical Center

View shared research outputs
Top Co-Authors

Avatar

Walter E. Pae

Penn State Milton S. Hershey Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elisabeth U. Dexter

State University of New York Upstate Medical University

View shared research outputs
Top Co-Authors

Avatar

Gerson Rosenberg

Pennsylvania State University

View shared research outputs
Top Co-Authors

Avatar

John L. Myers

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge